AcelRx Pharmaceuticals (NASDAQ:ACRX) Coverage Initiated at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) in a research report issued on Friday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

A number of other analysts have also recently issued reports on ACRX. Alliance Global Partners began coverage on shares of AcelRx Pharmaceuticals in a research note on Monday, October 2nd. They issued a “buy” rating and a $4.25 target price for the company. HC Wainwright reduced their price objective on shares of AcelRx Pharmaceuticals from $8.00 to $5.00 and set a “buy” rating for the company in a research note on Monday, September 25th.

AcelRx Pharmaceuticals Stock Up 3.1 %

NASDAQ ACRX opened at $0.49 on Friday. The stock has a market capitalization of $8.39 million, a PE ratio of -0.22 and a beta of 0.44. The company has a 50 day moving average price of $0.61 and a two-hundred day moving average price of $0.87. AcelRx Pharmaceuticals has a 12-month low of $0.43 and a 12-month high of $2.78.

Hedge Funds Weigh In On AcelRx Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. increased its position in AcelRx Pharmaceuticals by 1.0% during the third quarter. BlackRock Inc. now owns 1,947,140 shares of the specialty pharmaceutical company’s stock worth $407,000 after acquiring an additional 19,986 shares during the period. Renaissance Technologies LLC bought a new position in AcelRx Pharmaceuticals during the first quarter worth $27,000. Susquehanna International Group LLP bought a new position in AcelRx Pharmaceuticals during the fourth quarter worth $144,000. Values First Advisors Inc. increased its position in AcelRx Pharmaceuticals by 201.7% during the second quarter. Values First Advisors Inc. now owns 122,441 shares of the specialty pharmaceutical company’s stock worth $136,000 after acquiring an additional 81,854 shares during the period. Finally, Cowen AND Company LLC bought a new position in AcelRx Pharmaceuticals during the third quarter worth $67,000. Institutional investors own 19.79% of the company’s stock.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain.